Investigator-assessed PFS. (A) All randomly assigned patients. (B) Patients with ≥1 high prognostic risk factor including mutated TP53, uIGHV, del(11q), and/or CK. (C) Patients with uIGHV or mIGHV. (D) Patients with or without del(11q). CK, complex karyotype; HR, hazard ratio; mIGHV, mutated immunoglobulin heavy chain variable; NR, not reached; PFS, progression-free survival; uIGHV, unmutated immunoglobulin heavy chain variable.
Figure 1.

Investigator-assessed PFS. (A) All randomly assigned patients. (B) Patients with ≥1 high prognostic risk factor including mutated TP53, uIGHV, del(11q), and/or CK. (C) Patients with uIGHV or mIGHV. (D) Patients with or without del(11q). CK, complex karyotype; HR, hazard ratio; mIGHV, mutated immunoglobulin heavy chain variable; NR, not reached; PFS, progression-free survival; uIGHV, unmutated immunoglobulin heavy chain variable.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal